B3GNT3 siRNA (Human)

B3GALT8; TMEM3; UDP-GlcNAc:betaGal beta-1.3-N-acetylglucosaminyltransferase 3; BGnT-3; Beta-1.3-Gn-T3; Beta-1.3-N-acetylglucosaminyltransferase 3; Beta3Gn-T3; Beta-1.3-galactosyltransferase 8; Beta-1.3-GalTase 8; Beta3Gal-T8; Beta3GalT8; b3Gal-T8; Beta-3-Gx-T8; Core 1 extending beta-1.3-N-acetylglucosaminyltransferase; Core1-beta3GlcNAcT; Transmembrane protein 3; UDP-Gal:beta-GlcNAc beta-1.3-galactosyltransferase 8; UDP-galactose:beta-N-acetylglucosamine beta-1.3-galactosyltransferase 8

We offers pre-designed sets of 3 different target-specific siRNA oligo duplexes of human B3GNT3 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot.

Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.